Our clinical programme (CANFOUR Study)
Our clinical programme is initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer. The first study, CANFOUR, a ‘phase I/IIa study’, consists of two parts, with the first part evaluating the safety and tolerability of CAN04 at escalating dose levels, while the second part is designed to get an initial indication of anti-tumour activity in the chosen types of cancer. The first part of the trial is conducted by experienced investigators at five renowned clinics in Belgium, The Netherlands, Denmark and Norway and additional clinics will be added for the second part of the trial.
Dosage level and therapeutic efficacy
In the first part (phase I) of the initial study, CAN04 is administered to a limited number of patients to investigate the drug’s safety profile using gradually increasing dose levels. The documentation obtained will be used to find a safe and tolerable dose to continue with into the second part.
In the second part (phase IIa), CAN04 will be administered to a larger number of patients, with the aim to evaluate clinical activity and to further document safety. CAN04 is studied both as a stand-alone (mono) therapy and in combination with standard of care treatment for each indication.
Information about the clinical study can be found at clinicaltrials.gov - CANFOUR
Based on the results from the CANFOUR study the strategy for further clinical studies will be developed.
If you are interested in taking part in a clinical trial, please contact your doctor for advice.